iBio Is Not The Partner Of Mapp's Ebola Drug

| About: iBio, Inc. (IBIO)

Summary

Mapp's new partner will produce the drug using genetically modified mammalian cells.

IBIO's iBioLaunch is a plant-based platform.

It's not possible IBIO is the production partner.

iBio (NYSEMKT:IBIO) was up big on a massive 13.2M shares on Friday in response to speculation that it may be a manufacture partner in the government's efforts to ramp up production of Mapp Biopharmaceuticals' Ebola drug ZMapp. The stock price jumped another 70% in pre-market trading on Monday. However, a closer look at the news reveals that iBio cannot be the partner of ZMapp.

Based on UT San Diego news on Oct 9th, 2014, ZMapp's new partner will scale up a more traditional biotech process using genetically modified mammalian cells. That process uses "CHO" cells, derived from "Chinese hamster ovaries," grown in sterile tanks.

Bloomberg on 10/10/2014 also confirmed that the new partner will use Chinese hamster ovary cells for the new drug production.

However, IBIO's iBioLaunch is a plant-based platform. According to its website, The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, bacteria, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals.

A simple and quick piece of investigative work can make investors/traders avoid traps caused by unfounded rumors or even profit from it. If the truth is revealed in the next few days, iBio will tank hard as investors/momentum traders find out that iBio is not the partner at all. To make the situation worse, iBio entered into a $10M common stock purchase agreement with Aspire Capital Fund LLC. After its initial purchase of 1,136,354 shares at $0.44 per share, Aspire has committed to buying up to $9.5M in additional shares of common stock over a 24-month period. You can expect that Aspire Capital will take advantage of this rumor and hype to sell their shares purchased under $1.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

About this article:

Expand
Author payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.
Tagged: , , , Biotechnology
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here